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Background
Rituximab is a chimeric monoclonal antibody against the
surface protein CD20 of B cells, used in the treatment of
hematologic malignances and autoimmune diseases.
Some patients develop hypersensitivity reactions after the
infusion. It is unknown the percentage of these which are
due to an IgE allergic mechanism. Also, there is not a
standardized desensitization protocol that allows us to
induce tolerance to this drug in patients.
Methods
Patients with autoimmune diseases that have had a
hypersensitivity reactions to rituximab and have needed a
subsequent administration of the drug were included.
Skin tests (prick and IDR) at a concentration of 1 mg/ml
were performed on all patients and five controls. After-
wards, patients were hospitalized for 24 hours and a
modified desensitization protocol with three different
concentrations across a duration of nine hours was
initiated. Variations in the infusion rate and/or skip steps
were made in the following applications. Premedication
with acetaminophen, hydrocortisone and loratadine was
used in each desensitization.
Results
16 patients were included between October 2012 and
January 2014. 38 desensitization protocols were per-
formed. Skin tests were positive in one patient only
(IDR), and were negative in the rest of the patients and
the healthy controls. None of the patients had a serious
reaction during infusions and all of them tolerated the
whole dose of the drug.
Conclusions
Rituximab could be administered successfully and safely to
all the patients. Most of the reactions were infusion-
related (non allergic), probably explained by cytokine
release. More studies are needed to validate our findings.
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